The efficacy of COVID-19 vaccine for people with immunodeficiencies has not really been studied as, with the exception of people with well-controlled HIV infection (on therapy and with a CD4+ T‐cell count > 500), none of the registration trials included immunosuppressed subjects. The gene discussed is CD4; the disease is HIV infectious disease.